Jing Tai Technology (02228) included in MSCI China Index, global investment benchmarks recognize development potential.

On the morning of November 6th Beijing time, the globally renowned index company MSCI announced the results of the November 2025 index review. Crystal Tai Technology (02228), which is driven by artificial intelligence (AI) and Siasun Robot&Automation for innovation in new drugs and new materials, was selected to be included in the MSCI China Index, the flagship index most watched by MSCI. This adjustment is based on its semi-annual index review results in November, and will officially take effect after the market closes on November 24, 2025. Recognized as a global authoritative benchmark, the combination of artificial intelligence and Siasun Robot&Automation sets a benchmark for enterprises. This time, MSCI China Index added 26 new targets, including several resource stocks and technology companies such as artificial intelligence, Siasun Robot&Automation, semiconductors, and high-end manufacturing. Stocks entering the MSCI China Index mean they are included in the MSCI Global Standard Index series, attracting a large amount of passive fund tracking. The MSCI China Index is one of the key benchmarks for measuring the performance of large and mid-cap Chinese companies' stocks, widely tracked and referenced by global institutional investors. The screening of its index constituents is based on objective quantitative indicators, including company market capitalization, free float market capitalization, liquidity, and market investability. Being selected for this index indicates that Crystal Tai Technology meets strict international standards in terms of market value, market representativeness, and liquidity, and the company's investment value and growth potential have been recognized by global capital markets. Building a scarce technology platform, focusing on the industrialization of AI in vertical fields Crystal Tai Technology is an innovative research and development platform that deeply integrates quantum physics, artificial intelligence, and large-scale standardization experiments with Siasun Robot&Automation. It is also a pioneer in the field of Science Intelligence (AI for Science), having already partnered with over 300 international companies, innovative companies, and research institutions, and achieving profitability in the first half of 2025. Its business scope covers areas such as new drugs, energy, agriculture, new materials, new chemicals, and consumer products. Crystal Tai Technology is one of the very few AI research platforms that have obtained high-value collaborations with international pharmaceutical companies in both AI small molecule drug and AI biopharmaceutical research fields. Among the top 20 global pharmaceutical companies, 15 are clients of Crystal Tai Technology. Being selected for the MSCI China Index this time is a positive affirmation of Crystal Tai Technology's performance in the secondary market, business fundamentals, and future prospects. The company will take this opportunity to continue focusing on core technological innovation capability building, consolidate and accelerate the expansion of commercialization achievements, create greater value for global customers and partners, and bring sustainable long-term returns to investors.